Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fractyl Health (GUTS) Gains from Sales and Divestitures (2024)

Fractyl Health (GUTS) has disclosed Gains from Sales and Divestitures for 1 consecutive years, with $604509.0 as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Gains from Sales and Divestitures changed N/A year-over-year to $604509.0, compared with a TTM value of $604509.0 through Dec 2024, changed N/A, and an annual FY2024 reading of $604509.0, changed N/A over the prior year.
  • Gains from Sales and Divestitures was $604509.0 for Q4 2024 at Fractyl Health.
  • Across five years, Gains from Sales and Divestitures topped out at $604509.0 in Q4 2024 and bottomed at $604509.0 in Q4 2024.